2012 FNIH Annual Report
-
Upload
foundation-for-the-national-institutes-of-health -
Category
Documents
-
view
225 -
download
6
description
Transcript of 2012 FNIH Annual Report
COLLABORATIONFOR INNOVATION
2012 ANNUAL REPORT
Table of Contents
SCIENCE ....................................................... 2
TRAINING AND EDUCATION ..................... 10
EVENTS........................................................14
FUNDS AND ENDOWMENTS .................... 16
DONORS AND GIVING SOCIETIES ........... 21
FINANCIALS ............................................... 26
STAFF AND BOARD OF DIRECTORS........ 28
Foundation for the National Institutes of Health WWW.FNIH.ORG | 1
Letter from the Chairman
ria Freire, who joined us November 1st, as FNIH President and reire, who joined usreire, who joined usI am pleased to welcome Dr. Maria FI am pleased to welcome Dr. Maria F
ing as President of the Albert and Mary Lasker Foundation,as Presidas PresidExecutive Director. Most recently serving Executive Director. Most recently serving
mplishments in health research on a global scale. Dr. Freire’s career is remarkable in its accompliDr. Freire’s career is remarkable in its accompli
ation with the National Institutes of Health (NIH),Dr. Freire enjoys a long associationDr. Freire enjoys a long association
ansfer from 1995 to 2001 and serving as adirecting its Office of Technology Transfdirecting its Office of Technology Transf
e NIH Director from 2008 to 2012. Thismember of the Advisory Committee to the NIHmember of the Advisory Committee to the NIH
fulfill our mission to support the established relationship will enrich our ability to fulfiestablished relationship will enrich our ability to fulfi
NIH on many levels.NIH on many levels.
ion of partners fromIn 2012, our portfolio of work embraced a broad constellation In 2012, our portfolio of work embraced a broad constellation
nonprofit sector as well asrofit serofit semany institutes and centers within the NIH, from the nonmany institutes and centers within the NIH, from the non
echnology, retail, and food and ogy, retail, aogy, retail, athe private sector, including pharmaceutical, technthe private sector, including pharmaceutical, techn
ons as diverse as the National Footballdiverse as the Natdiverse as the Natbeverage industries and from organizations abeverage industries and from organizations a
League and Google.League and Google.
as a trusted, neutral convener remains fundamental rusted, neutral convener remains rusted, neutral convener remains As we expand and refine activities, our role as aAs we expand and refine activities, our role as a
e do. This pivotal position enables us to channel expertise, This pivotal position enables us to channThis pivotal position enables us to channto who we are and integral to what we doto who we are and integral to what we do
resources and funds from multiple and diverse partners to address common challenges efficiently,d diverse partners to address common challed diverse partners to address common challeesources and funds from multiple aesources and funds from multiple a
effectively and ethically. In doing so, we ensure that the sum of our efforts is greater than their g so, we ensure that the sum of our efforts is greateg so, we ensure that the sum of our efforts is greatevely and ethically. In dovely and ethically. In do
discrete parts. In short, the FNhe FNIH promotes collaboration for innovation.he FNIH promotes collaboration for innovation.ts. In short, ts. In short,
rles A. Sanders, M.D.
ateful to the“It is a great honor to head this remarkable organization. I am gra“It is a great honor to head this remarkable organization. I am gra
look forward FNIH Board, staff, partners and funders for this opportunity and FNIH Board, staff, partners and funders for this opportunity and
to working with all in the years to come.” to working with all in the years to come.”
Maria C. Freire, Ph.D.,Maria C. Freire, Ph.D.,
President and Executive DirectorPresident and Executive Director
Charles A. Sanders, M.D.
Chairman
SCIENCE
“FNIH has demonstrated its ability to conduct
complex transactions quickly and efficiently.
Working with FNIH to pursue mutual goals shared
with the Bill & Melinda Gates Foundation’s CAVD
will expedite the Vaccine Research Center’s
development of novel passive-active strategies
for prevention of HIV infection.”
Gary Nabel, M.D., Ph.D., Senior Vice President for Global R&D, Sanofi; former Director of the Vaccine Research Center, NIAID
Foundation for the National Institutes of Health WWW.FNIH.ORG | 3
Sports and Health Research Program With a $30 million donation, the National
Football League (NFL) became the founding
partner of the FNIH’s new Sports and Health
Research Program. While specific initiatives
have yet to be finalized, potential areas of
research include brain injury, sudden cardiac
death, heat and hydration-related illness,
joint disease, health effects of performance-
enhancing substances and chronic pain.
Traumatic brain injury (TBI) is an important area
of interest for professional football and other
contact sports. Research, to better understand
ways to recognize and prevent brain injury, is
a major focus of discussions within this new
program. The impact of research on brain
injury will extend far beyond the NFL, as TBI
is the signature wound of soldiers fighting in
Iraq and Afghanistan, and each year, across
America, an estimated
1.7 million people suffer a brain injury due
to trauma.
The Sports and Health Research Program
aims to attract funding from other donors,
including additional sports organizations.
The founding grant represents the NFL’s
single largest donation to any organization
in the league’s 92 years.
Biomarkers Consortium A wide-ranging initiative to advance precision
(personalized) medicine, the Biomarkers
Consortium works to identify measurable
indicators of biological and pathological
processes to predict, prevent and treat
disease. Among the projects underway are:
I-SPY 2 Women newly diagnosed with aggressive
breast cancer should have more rapid access
to promising therapies thanks to new Food and
Drug Administration (FDA) draft guidelines (or
guidance) based on the FNIH I-SPY 2 study.
I-SPY 2, a project of the Biomarkers
Consortium, is pioneering a novel protocol
to test and gain approval for new drugs, a
process that is notoriously slow and expensive.
Currently, it can take more than a decade to
bring a new cancer drug to market at a cost of
Research: Program Highlights In 2012, FNIH programs encompassed a broad spectrum of biomedical research—from precise, innovative fundamental work to understand disease and its progression, to clinical and field trials to evaluate potential new therapeutic interventions, to large-scale methods to monitor the effects of existing medicines. Through FNIH, private-sector organizations with an interest in a disease or a new technology can team up with the NIH to accelerate the pathway from collaboration to innovation.
more than $1 billion—time many breast cancer
patients simply do not have.
The trial’s approach is groundbreaking in two
ways: first, it is screening various potential
new drugs within the same study; as these
candidate drugs are moved out—either for
next-stage testing or because they fail—new
ones are introduced. Second, instead of a
one-size-fits-all trial, candidate drugs are
assigned to patients based on the specific
characteristics of their tumor.
The draft FDA guidance on the subject
suggests that once these new drugs have
shown clinical benefit in the I-SPY 2 model,
they should be eligible for accelerated
regulatory approval following a confirmatory
trial. The goal of I-SPY 2 is to cut the time to
develop a drug in half and dramatically lower
the costs.
Consensus Definition of Clinically Important Sarcopenia This Biomarkers project team has completed
its work in advancing the first evidence-based
definition of sarcopenia (muscle weakness), a
condition that results in serious consequences
such as disability and increased mortality.
In the first phase of the project, six principal
investigators analyzed pooled data from
clinical trials and large observational studies,
such as the Health ABC and Framingham
studies. Their findings, reported at a four-day
Sarcopenia Consensus Summit in May 2012,
are being readied for publication. The new
definition will assist researchers, clinicians
and regulators in diagnosing sarcopenia and
the consensus-building process will serve as
a model for articulating other evidence-based
definitions of geriatric health problems.
Several other Biomarkers Consortium projects marked significant milestones in 2012 as well:
Researchers on a diabetes project to identify
biomarkers that predict the performance
of insulin-producing cells in the pancreas
completed their studies of healthy, pre-
diabetic and diabetic patients and will
present findings at the American Diabetes
Association meeting in the summer of 2013.
A project team working to help researchers
develop drugs that minimize kidney injury
completed a retrospective analysis and
launched two clinical studies, together
enrolling 300 patients.
An atherosclerosis modeling project was
launched in September 2012. This two-year
effort will integrate existing biomarker data
into one comprehensive computer-based
disease model to identify which measures
best predict clinical outcomes such as heart
attack and stroke.
A project aimed at aiding the development of
new antibiotics against community-acquired
bacterial pneumonia and acute bacterial
skin infections entered its second phase.
The team published a paper in the journal
Clinical Infectious Diseases on its efforts
and progress to date. The clinical end points
established by this project have proven vital
to the approval of several antibacterial drugs.
Foundation for the National Institutes of Health WWW.FNIH.ORG | 5
Alzheimer’s Disease Neuroimaging Initiative 2 Now in its eighth year, the Alzheimer’s Disease
Neuroimaging Initiative (ADNI) is the largest
public-private brain research partnership to
date, with 28 private partners coordinated by
the FNIH. It remains the gold standard for how
such partnerships can advance biomedical
research. ADNI data, collected on the study’s
1,500 participants, is placed in the scientific
public domain to encourage its use by the
broadest range of investigators possible.
The accomplishments from this program
continue to inform development of new
therapies as well as influence additional
studies. Under the organization of the
Alzheimer’s Association’s World-Wide ADNI,
similar work is being carried out in Argentina,
China, Europe, Japan, Australia, Taiwan and
South Korea.
Building on the success of the program, ADNI
has garnered additional support from the
Brin Wojcicki Foundation and the Alzheimer’s
Association to conduct whole genome
sequencing on 818 study participants. This
effort will exponentially increase the amount
of genetic data available to investigators, likely
highlighting a wealth of new targets for risk
assessment, insights and therapies.
Complementary to the scope of ADNI, the
program’s investigators have received support
from the Department of Defense to follow 300
Vietnam veterans, aged between 60 and 90
years old, to study whether traumatic brain
injury and/or post-traumatic stress disorder—
both common battlefield injuries—increase the
risk of Alzheimer’s disease later in life.
SPIROMICS Although it is the third-leading cause of death
in the United States, affecting as many as 24
million people, chronic obstructive pulmonary
disease (COPD) is still poorly understood and
treatment options are limited. SPIROMICS, or
SubPopulations and InteRmediate Outcome
Measures In COPD Study, is an observational
study with two main goals. The first is to
identify subpopulations of COPD patients that
share common characteristics. The second is
to identify biomarkers that will enable better
tracking of the disease’s progression. Together,
these efforts should improve the ability of
clinical trials to determine whether particular
therapies are working.
Six university clinical centers are working in
partnership with the National Heart, Lung and
Blood Institute to follow 3,000 COPD sufferers.
Observational Medical Outcomes Partnership America’s drug-approval process has set
the global standard for rigorous safety and
effectiveness review, but even with clinical
trials and other safeguards, it is impossible to
fully understand the impact of any particular
medical intervention until it is widely used.
Once drugs are on the market, researchers
continue to study them to identify safety issues
and potential unanticipated benefits.
In 2007, recognizing that the increased use
of electronic health records and availability of
other large sets of health data provided new
learning opportunities, Congress directed the
Food and Drug Administration (FDA) to create
a new drug surveillance program to more
aggressively identify potential safety issues.
In response, together with PhRMA and the
FDA, FNIH launched the Observational
Medical Outcomes Partnership (OMOP).
This interdisciplinary, public-private research
group is engaged in identifying the most
reliable methods for analyzing huge volumes
of data drawn from heterogeneous sources to
identify drug safety issues. Over the course
of 2011 and 2012, research yielded greater
confidence that particular methods used with
specific types of data can reliably identify
correlations between individual medical
interventions and specific health outcomes.
As experiments continue to provide greater
understanding of how health care data can
be analyzed effectively, OMOP will continue
to evaluate how large-scale empirical
experiments can be refined for maximum
clinical benefit and improved decision-making.
Global Health Collaborating with organizations around
the world, FNIH furthers the understanding
and control of diseases that sicken and kill
hundreds of millions of people every year.
Working in the U.S. and internationally, FNIH-
funded investigators are making strides
against life-threatening diseases including
malaria, dengue, tuberculosis, enteric
infections and malnutrition.
Grand Challenges in Global Health The Grand Challenges in Global Health
(GCGH) is a partnership with the Bill &
Melinda Gates Foundation that fosters
innovative research to address scientific
obstacles that block progress against
diseases prominent in developing countries.
FNIH is involved with several groundbreaking
components of the program.
“Concerning our understanding of the effects of medical products, both benefits and harm, OMOP has demonstrated crucial lessons for pharmacoepidemiology using huge volumes of data. We refined our strategies by selecting the analytical method that produces the greatest accuracy in predicting known health outcomes as well as the method most effective for each data source. We are challenging traditional thinking in epidemiology and exploring new designs.”
David Madigan, Ph.D., OMOP Research Investigator and Professor and Chair of Statistics, Columbia University
Foundation for the National Institutes of Health WWW.FNIH.ORG | 7
The Vector-based Control of Transmission:
Discovery Research (VCTR) program is an
extension of GCGH focused on development
of biologic, genetic or chemical strategies
to control mosquito-borne diseases. In
2012, testing of a promising dengue control
technology that originated in Australia was
expanded to additional field sites in Brazil and
Vietnam. Researchers are working to inhibit
the transmission of dengue virus through
a biocontrol method—infecting the Aedes
mosquitoes that spread the disease with a
bacterium that reduces viral replication in the
mosquito and, consequently, the amount of
virus present in the insects’ saliva to be passed
on when it bites. Australian field trials continue
to compare the effects of different strains of
Wolbachia bacteria on viral development within
the mosquitoes as a marker to predict effects
on dengue transmission.
Investigators in several African countries
joined a consortium working on a new genetic
method to decrease the spread of malaria. The
researchers are developing ways of inserting
an enzyme into Anopheles mosquitoes that
carry the disease. The enzyme will be targeted
to inactivate a gene required for mosquito
reproduction. By inhibiting their capacity
to reproduce, the scientists aim to reduce
mosquito numbers below the level necessary
to maintain malaria transmission.
A completely different approach to interrupting
malaria transmission brings academic and
industry researchers together to screen and
test hundreds of thousands of compounds
for their potential effects on mosquito host-
seeking behavior. Several of the most effective
compounds are already being pursued for
further development, with the goal of creating
better repellents.
Etiology, Risk Factors & Interactions of Enteric Infections and Malnutrition and the Consequences for Child Health & Development (MAL-ED) This partnership with the Bill & Melinda Gates
Foundation and the Fogarty International
Center at NIH, is designed to increase
understanding of the complex interactions
among enteric infections and malnutrition
and their association with impaired growth
and cognitive development and poor vaccine
efficacy in young children.
In February 2012, enrollment was completed
in a large birth cohort study. Researchers
are monitoring nearly 2,000 children—across
eight field sites in rural and urban settings
on three continents—through their first two
years of life. They are collecting and testing a
variety of biospecimens to identify specific risk
factors for growth and development shortfalls.
Early data suggest intriguing differences and
similarities among the sites—valuable insights
that will inform the design of appropriate
interventions.
Identification of High-Quality HITs for Tuberculosis (HIT-TB) This partnership with the Bill & Melinda Gates
Foundation and the National Institute of Allergy
and Infectious Diseases (NIAID), screens
chemical libraries to identify molecules that
could lead to better drugs against tuberculosis.
HIV/AIDS Vaccine Development FNIH serves as the primary awardee for three
research projects that are part of the Bill &
Melinda Gates Foundation’s Collaboration
for AIDS Vaccine Discovery (CAVD). On each
project, the Vaccine Research Center at NIAID
works in collaboration with other institutions to
develop new vaccines to prevent HIV/AIDS.
In 2012, partners at the Vaccine Research
Center made significant progress in
characterizing T and B cell vaccine responses.
A new technology (Fluidigm) allows rapid and
economical screening of hundreds of single
cells for many different markers, facilitating a
more precise understanding of an individual’s
immune status. This advance holds great
promise for expanding the ability to monitor
immune responses to vaccination or infection.
Discussions with the FDA have advanced
planning for a proof-of-concept clinical trial
with the potential to expedite regulatory review
of synthetically designed vaccine inserts.
This three-armed trial will compare wild-type
HIV Env vaccine constructs with mosaic and
consensus constructs to determine relative
safety and efficacy. This approach will facilitate
the design of broadly protective HIV vaccines.
CAVD Projects:The Comprehensive T Cell Vaccine Immune
Monitoring Consortium (CTVIMC), now in
its seventh year, provides standardized,
validated clinical end-point and research
assays for the development and licensure
of a vaccine to prevent AIDS.
The Centralized Envelope Comparative
Immunogenicity Study (CECI) brings together
stakeholders across the Global HIV Vaccine
Enterprise to answer a fundamental and
central question blocking the development
of a successful HIV-1 vaccine: how to design
an AIDS vaccine that will induce protective
cellular immune response against the many
genetically diverse types of HIV-1 that are
found around the world.
The Development of a Second Generation
Broadly Neutralizing Antibody Product to
Prevent HIV-1 Infection in Humans builds
on the recent identification of broadly
neutralizing antibodies in humans that
block the ability of HIV to infect human T
cells. The goal of this project is to optimize
the potency and half-life of monoclonal
antibodies suitable for treatment of HIV/AIDS
and to provide new information for design of
antibody-based vaccines.
Additional Research Partnerships: ADNI Cerebral Spinal Fluid (CSF) Extension
Age-Related Eye Disease Study 2 (AREDS2)
Ancillary Study
Alzheimer’s Disease Neuroimaging Initiative -
Optimization of Alzheimer’s Disease Cognitive
Measures
Placebo Data Analysis Project in Alzheimer’s
Disease/Mild Cognitive Impairment Clinical
Trials (Neuroscience)
Burkitt Lymphoma Genome Sequencing
Project (BLGSP)
Clinical Center Drug Donations
Comparison of Two PET Radioligands to
Quantify the Peripheral Baenodiazepine
Receptor
Development and Production of Endotoxin
under GMP for Human Clinical Research
Drug Induced Liver Injury Network (DILIN)
Epigenetic and Immunoregulatory Control of
Ocular Inflammatory Disease
Foundation for the National Institutes of Health WWW.FNIH.ORG | 9
Evaluation of the Effect of Negative
Costimulatory Signals on the Model of
Experimental Autoimmune Uveitis (EAU) Using
the Ig Fusion Construct AMP-110
Hemodialysis Fistula Maturation Cohort Study
Hereditary Hyperhomocysteinemia–An
Underestimated Disease?
Housing for Chimpanzees Retired from
Biomedical Research
Human Microbiome Project
Demonstration Projects
Human Papilloma Virus Clinical Trial
(HPV-GSK)
Induced Pluripotent Stem Cell Consortia
Measures for Clinical Trials of Treatment of
Cognitive Impairment
Mutational Analysis of the Melanoma Genome
Neurotropin Research Project
Osteoarthritis Biomarkers Project
Osteoarthritis Initiative Extension (OAI 2)
Overcoming Barriers to Early Phase Clinical
Trials
PATH Youth Program: HIV/AIDS in Adolescents
Phase II Trial of IPH2101 (anti-KIR) in
Smoldering Multiple Myeloma
Progressive Multifocal Leukoencephalopathy
Data Registry
Research Partnership in Cognitive Aging
Schizophrenia Metabolic Initiative (SMI-BMS)
Senior Independent Living Research Network
T Regulatory Cells as a Peripheral Marker
for the Development of Age-related Macular
Degeneration (AMD) and Uveitis
Testing for MMTV and Related Retroviruses in
Breast Cancer
Time Efficient Automatic Lesion Identification
and Measurement on CT
Use of Targeted Multiplex Proteomic Strategies
to Identify CSF-Based Biomarkers in
Alzheimer’s Disease
TRAINING AND EDUCATION
“The future promises remarkable advances in
biomedical research. To attain that goal, we
need broad, transformative training for clinician
scientists. It is time to invest boldly in new
ways of learning so that the next generation of
innovative thinkers can open new frontiers in
knowledge and transform medicine.”
Francis Collins, M.D., Ph.D. NIH Director
Foundation for the National Institutes of Health WWW.FNIH.ORG | 11
Medical Research Scholars Program The inaugural class of the Medical Research
Scholars Program began training on the NIH
campus last fall. The program welcomed 45
of the best and brightest young researchers
from 34 medical, dental and veterinary
schools across the country. During the year-
long program, the students conduct basic,
translational or clinical research in a field of
their choice, guided by a mentor and a tutor.
To foster the next generation of medical
researchers and clinician-scientists committed
to translational research and the promise it
holds for the conquest of disease, the program
immerses students in the full continuum of
biomedical research early in their career
training. In addition to their research work,
students complete an academic curriculum
and interact with NIH scientific leaders—
institute directors, clinical directors and
established investigators.
The program merges and builds on two
earlier, highly successful training programs,
the Howard Hughes Medical Institute-NIH
Research Scholars Program and the Clinical
Research Training Program. The goal is to
support 70 scholars each year.
Training and Education While technology plays an increasingly vital role in advancing human health, progress is impossible without a new generation of capable and curious researchers. FNIH programs in various formats target a wide array of topics and education levels, making the world-class methods and resources of the NIH available to students and researchers all over the world.
Additional Training, Education Programs and Fellowships: Bernard Osher Foundation NCCAM
Practitioner Research Career
Development Award
Clinical Research Training Program (CRTP)
Laboratory Animal Medicine Resident
Training Program
NINR Research Fellow Ralph Michael Peace
Oxford Cambridge Scholarship Program
Pew Latin American Fellows Awards
Principles of Clinical Pharmacology Course
Targeting MMP Using Three-dimensional
Culture of Human Breast Cancer
Tracking intracellular nanoparticle dynamics
and cytotoxic/epigenetic signatures both in
vitro and in vivo using advanced cytometry
and multimodal imaging
US-Russia Collaboration in the Biomedical
Sciences Fellowship Program
World AIDS Foundation-Clayton-Dedonder
Scholarships
Foundation for the National Institutes of Health WWW.FNIH.ORG | 13
Human Genome Exhibition Employing the world-renowned expertise of
the Smithsonian Institution to interpret complex
concepts for the general public, a new
exhibition will tell the story of the discovery
of the human genome. A FNIH partnership
with the National Human Genome Research
Institute and the National Museum of Natural
History, the interactive exhibit will open in June
of 2013—the 10th anniversary of the mapping
of the human genome and the 60th anniversary
of the discovery of the double-helix structure
of DNA.
One of the great feats of exploration in history,
the Human Genome Project unlocked a new
dimension in science and healthcare—yet
it remains largely inscrutable to the general
public. Accompanied by a dynamic education
and outreach program, the hands-on exhibit
will trace the history of the project and reveal
the enormous impact genomics has had on
individuals, humanity and the natural world.
Themes will include health and medicine,
ethics, biodiversity, ancestry and what the
future may hold.
After its run of at least one year at the Natural
History Museum in Washington, D.C., the
exhibit will travel nationally, bringing the
wonders of this achievement to thousands
around the U.S.
“Through the exhibition, we aim to help the public see how the Human Genome Project set the stage for the modern era of genomics. With this have come spectacular opportunities for using genomics to expand our knowledge of the human body in health and disease and to understand the underpinnings of biodiversity in the natural world.”
Eric D. Green, M.D., Ph.D., Director, National Human Genome Research Institute
EVENTS
Alzheimer’s Disease Summit
“The FNIH’s support of the Alzheimer’s Disease Summit was instrumental in bringing together over 500 researchers and the advocate community to focus on the way forward in finding treatments for this terrible disorder. The summit fulfilled a major goal of the new National Plan to Address Alzheimer’s Disease, that of convening national and international scientists to identify priorities and milestones to reach our goal of preventing or treating Alzheimer’s by 2025.”
—Kathleen Sebelius, Secretary, Department of Health and Human Services. The Summit was hosted by the Department of Health and Human Services and the National Institute on Aging, with the support of the FNIH.
Foundation for the National Institutes of Health WWW.FNIH.ORG | 15
The Heart Truth®
Marking a decade of educating women aboutMarking a decade of educating women about
the importance of heart health in 2012, Thethe importance of heart health in 2012, The
Heart Truth® campaign has attracted a wide Heart Truth® campaign has attracted a wide
range of support—from individual knitters to range of support—from individual knitters to
large corporations.large corporations.
Education has been shown to be an importantEducation has been shown to be an important
factor in lowering the risk for heart disease.factor in lowering the risk for heart disease.
ute The National Heart, Lung and Blood Institute The National Heart, Lung and Blood Institute
n, reportsportsports(NHLBI), which created the campaign, re(NHLBI), which created the campaign, re
that women who are aware that heart dit diseaset diseasethat women who are aware that hethat women who are aware that he
is the number-one killer of womeomen areomen arethe number-one killer of the number-one killer of
significantly more likely to tato take positiveto take positiveantly more likelyantly more likely
action than those whowho are not.who are not.hoshos
dition to working with sponsors, FNIHIn additioIn additio
s the community action grant administers thadministers th
ad the word—particularly to program to spread tprogram to spread t
rity communities. In 2012, low-income and minoritylow-income and minority
00,000 to five organizations0 to 0 to FNIH awarded $300,0FNIH awarded $300,0
communities from Washington unities frounities froworking in commworking in comm
o Connecnecticut.necticut.State to CState to C
Outreach and fundraising activities included utreach and fundraising autreach and fundraising aOO
Collection—theunveiling of the Red Dress Cunveiling of the Red Dress C
he Heart Truth®Red Dress is a symbol of thRed Dress is a symbol of th
rk Fashion Week campaign—during New Yorcampaign—during New Yor
m created by Jimmyand the Stitch Red programand the Stitch Red program
Beans Wool.Beans Wool.
Additional Events and Outreach Grants: Google Ad GrantGoogle Ad Grant
ute (NCI) SmallThe National Cancer InstituThe National Cancer Institu
arch (SBIR) ForumBusiness Innovation ReseaBusiness Innovation Resea
al Medical SciencesNational Institute of GeneraNational Institute of Genera
Stetten Symposium(NIGMS) 50th Anniversary (NIGMS) 50th Anniversary
nd Disease –Dendritic Cells in Health anDendritic Cells in Health an
nA Tribute to Ralph SteinmaA Tribute to Ralph Steinma
urementAlzheimer’s Disease MeasuAlzheimer’s Disease Measu
enceImprovement ConferenceImprovement Conference
mmitmHealth SummmHealth Summ
IH/FDA Glycosciences Research DayNIH/FNIH/F
Events Collaboration happens when people connect. That is why managing and organizing meetings and events is fundamental to the work of the FNIH. From lectures and workshops to collaborative summits, teleconferences and media opportunities, the FNIH facilitated more than 60 events in 2012—spanning the globe and dozens of fields of research.
FUNDS AND
“Since its founding in 1996, FNIH has raised
almost $700 million for vital programs in health
and biomedical research and has assembled
coalitions that otherwise might never have
been possible.”
Maria Freire, Ph.D., President and Executive Director, FNIH
Foundation for the National Institutes of Health WWW.FNIH.ORG | 17
Named Funds Named funds are created to support specific
areas of research or fellowships, lectures or
awards at the NIH.
Gramlich Melanoma Research Fund This fund supports melanoma research at the
NIH through an annual gift provided by the
Jack Gramlich Foundation.
The Dr. Franklin A. Neva Memorial Fund The Neva Fund was established by the family
of Dr. Frank Neva, a former director of the
NIAID Laboratory of Parasitic Diseases (LPD)
at the NIH, to honor his memory and further
his legacy.
Dr. Neva was keenly interested in teaching and
learning through case-based discussions and
he transformed the LPD into a pre-eminent
center for basic and clinical parasitology
research and training.
Sayer Vision Research Fund This fund supports the annual Sayer Lecture
delivered by an investigator in the area of
vision research, as well as the Sayer Vision
Research Award, given to a promising
independent investigator in the early stage
of his or her research career in the Division
of Intramural Research at the National Eye
Institute. The fund was established by NIH
research scientist Jane Sayer, in honor of her
family and in memory of her parents, Winthrop
and Laura Sayer.
Swanson Family Fellowship The Swanson Family Fellowship supports
research in TTF-1 mutation-causing benign
chorea in the laboratory of infectious diseases
under the direction of Steven M. Holland, M.D.,
Chief of the Laboratory of Clinical Infectious
Diseases, NIAID.
Funds and Endowments Funds and endowments established at the FNIH are a lasting way for individuals and organizations to pay tribute to special people or causes through ongoing support of research, education or events in biomedicine at the National Institutes of Health (NIH). Large or small, such gifts are a testament to the impact every person can make on discoveries that advance human health.
Memorial Funds Memorial funds create a living legacy. In many
cases a family member may request that
friends and relatives make donations—rather
than send flowers—to support a chosen cause
in memory of a loved one. Families may wish
to go one step further and establish a fund
that embodies a loved one’s passion and
spirit by making a significant investment in
the Foundation.
Dr. John L. Barr Memorial Fund This fund helps to support the Intramural
Research Training Award Fellowship Program
at the NIH Clinical Center’s Pain and Palliative
Care Service. The goal of the fellowship is
to conduct research on pain and palliative
care and to encourage young investigators to
become more familiar with the importance of
this field of study.
Adam J. Berry Memorial Fund This fund was established by Michael and
Sue Berry in memory of their beloved son,
Adam. Adam came from Australia to work as
a research scientist at the National Cancer
Institute (NCI). The fund commemorates his
life and his enthusiasm for work by making
it possible for promising young Australian
scientists to travel to the United States and
work at the NIH.
Edna Williams Curl and Myron R. Curl Fund for Multiple Sclerosis Research
Established in 2007, this fund supports multiple
sclerosis research at NIH.
John Laws Decker Memorial Fund
A former director of the NIH Clinical Center, Dr.
John Laws Decker strived during his lifetime
to accelerate important scientific research by
linking research communications around the
world. His dedication led the NIH to establish
an annual lecture in his name. This fund,
established by the Decker family, supports an
event for the lecturer each year.
Dean R. O’Neill Renal Cell Cancer Research Fund
This fund supports a fellowship in the
laboratory of tumor immunology headed
by Richard Childs, M.D., at NHLBI. The
postdoctoral cancer investigator funded by the
program conducts research on the treatment
of renal cell (or kidney) cancer.
Family and friends of the late Dean O’Neill estab-
lished the fund; more information can be found
at www.renalcellcancer.org. The family also orga-
nizes the annual Boo! Run for Life 10K race and
two-mile walk to support the fund. Information
about the Boo! Run, held annually in October,
can be found at www.boorunforlife.com.
Dr. Edward T. Rancic Memorial Fund
This fund supports a post-doctoral fellowship
that focuses on renal cell cancer research in
the laboratory of tumor immunology headed by
Richard Childs, M.D., at NHLBI. The fellowship
was established in memory of Dr. Edward
Rancic by his family.
Foundation for the National Institutes of Health WWW.FNIH.ORG | 19
Dr. Anita Roberts Memorial Fund
Widely recognized as an outstanding mentor,
encouraging and inspiring young scientists,
Dr. Roberts was one of the first female
laboratory chiefs at the NIH and ranked in
the top 50 most-cited biological scientists
in the world. Her family and laboratory
colleagues established the fund to allow
graduate students and post-doctoral fellows
to present their work at a national meeting,
typically the TGF-beta Keystone Symposium.
These scholarships are a fitting tribute to Dr.
Roberts’ passion for encouraging the career
development of young scientists.
Tracy’s Toy Box
Established by the family in memory of Tracy
Nadel, this fund purchases toys and activities
for children staying at the Edmond J. Safra
Family Lodge. These items help make their
time at the Lodge more comfortable
and pleasant.
Robert Whitney Newcomb Memorial Fund This fund was established by the family to
remember Dr. Newcomb, who began his
scientific career at the NIH as a high school
summer intern in a laboratory at the NCI.
The fund endows an annual lecture by a
recognized expert in neuroscience, selected
by the National Institute of Neurological
Disorders and Stroke (NINDS). Honoring Dr.
Newcomb’s own experience, it also provides
for internships for high school students and
fellowships at NINDS.
Stephen J. Solarz Memorial Fund Nina Solarz established this fund in memory
of her husband, former Congressman Steve
Solarz, to support the research of Dr. David
Schrump at NCI. Dr. Schrump’s pioneering
research in the field of thoracic oncology led
to the treatments that allowed Mr. Solarz to
live years beyond what otherwise would have
been possible. Before he died, Nina and her
family dedicated themselves to supporting
Dr. Schrump’s research so that other patients
might benefit by even better treatments.
Stephen E. Straus Fund Established by Bernard and Barbro Osher in
2006, this fund honors the founding director of
the NIH’s National Center for Complementary
and Alternative Medicine (NCCAM), the late Dr.
Stephen E. Straus. It supports the Stephen E.
Straus Distinguished Lecture in the Science
of Complementary and Alternative Medicine,
an annual lecture that brings leading figures
in science and medicine to the NIH to speak
about their perspective on the field. Open
to the public, the lecture is videocast and
archived on the NCCAM website.
Endowments Through these endowment gifts, donors
ensure perpetual support for a variety of
research and educational initiatives at FNIH.
The annual investment income generated by an
endowment fund supports program expenses,
while the principal remains intact to ensure
future funding.
Sallie Rosen Kaplan Fund for Women Scientists in Cancer Research
The Kaplan Fund, established in 2000,
provides support for the Sallie Rosen Kaplan
Fellowships for Women Scientists in Cancer
Research. These post-doctoral fellowships are
awarded to one or more outstanding female
scientists at the NCI.
Norman P. Salzman Memorial Fund Dr. Salzman’s family, colleagues and friends
remember the legacy of this noted pioneer in
molecular biology through contributions to this
fund, which supports the annual Norman P.
Salzman Memorial Award and Symposium in
Virology. The half-day symposium addresses
key topics in virology and immunology and
presents an award to a young researcher, in
recognition of Dr. Salzman’s mentorship of so
many younger scientists.
Endowments in support of the Edmond J. Safra Family Lodge
Through endowment gifts, donors ensure
perpetual support to the Edmond J. Safra
Family Lodge for its operations and for the
continued comfort of its guests.
John I. and Elaine K. Gallin Endowment The Gallin Endowment provides amenities for
family members of patients participating in
clinical trials at the NIH.
GlaxoSmithKline Endowment The GlaxoSmithKline Endowment supports
programs and activities for families, including
services that help residents stay in touch with
employers and loved ones.
Harry and Jeanette Weinberg Endowment The Weinberg Endowment supports
Edmond J. Safra Family Lodge operations
and maintenance—ensuring that guests are
provided a comfortable home away from home
for years to come.
Additional Funds: Jerry D. Jennings Memorial Fund
NCI Neuro Oncology Branch Fund
Pain and Palliative Care Program,
Roxane Institute Fund
Research in Congenital Adrenal Hyperplasia
Foundation for the National Institutes of Health WWW.FNIH.ORG | 21
DONORS AND GIVING SOCIETIES
“…On Monday, 14 May, the Jewels for Hope:
The Collection of Mrs. Lily Safra auction at
Christie’s Geneva was a wonderful success.
Thanks to the sale of this jewelry, the Lily Safra
Foundation will be able to provide $1 million to
each of 32 extraordinary organizations around
the world, and I am delighted that the Edmond J.
Safra Family Lodge at the NIH is among these.”
Mrs. Lily Safra, Chair, Lily Safra Foundation; FNIH Board Member
Donors
$5,000,000+
Bill & Melinda Gates Foundation 11
National Football League
$2,500,000 – $4,999,999
Johnson & Johnson 12
$1,000,000 – 2,499,999
Amgen, Inc. 10
Eli Lilly and Company 13
McKnight Brain Research Foundation 7
Merck Sharp & Dohme Corp.15
Novartis Pharmaceuticals Corporation 13
Pfizer Inc 15
Pharmaceutical Research and Manufacturers of America 8
Mrs. Lily Safra 11
$500,000 – $999,999
Abbott Laboratories 5
AstraZeneca LP 11
Avon Foundation for Women 2
Doris Duke Charitable Foundation 10
Ann Lurie
National Institutes of Health 17
QuantumLeap Healthcare Collaborative 3
Takeda Pharmaceuticals Company Limited 4
$250,000 – $499,999
Alzheimer’s Association 8
Arthritis Foundation, Inc. 3
Bausch & Lomb 2
Biogen Idec 2
Paula L. and William C. Bradley 5
The Brin Wojcicki Foundation
Bristol-Myers Squibb 13
Critical Path Institute and the Predictive Safety Testing Consortium 2
Eisai Inc. 6
GlaxoSmithKline 14
Healthcare Information and Management Systems Society
The Leona M. and Harry B. Helmsley Charitable Trust
Robert Wood Johnson Foundation 9
Nippon Zoki Pharmaceuticals Co., Ltd.
Novo Nordisk A/S 2
The Bernard Osher Foundation 4
Roche 6
The Safeway Foundation 2
Sanofi 11
Temptime Corporation 2
$100,000 – $249,999
Alere Inc. *
Bioiberica S.A. 2
Boehringer Ingelheim Pharmaceuticals, Inc. 5
Celgene Corporation 3
The Coca-Cola Company 5
Daiichi Sankyo, Inc. 3
Elan Pharmaceuticals
Flexion Therapeutics, Inc.
Howard Hughes Medical Institute
Mike and Beth Hunkapiller
IBEX Technologies Inc. *
Immunodiagnostic Systems Holdings PLC *
Institut De Recherches Internationales Servier 3
IXICO Ltd.
NeuroRx
Pacific Biosciences
Piramal Imaging, GmbH 2
Swarovski North America, Ltd. 3
$50,000 – $99,999
American Diabetes Association 3
Amylin Pharmaceuticals, Inc. 3
AXA Research Fund
Peter D. and Karen N. Bell
CTIS Inc. 3
Dairy Research Institute 2
The Dannon Company, Inc. and Nutricia 3
DePuy Mitek, Inc.
Innogenetics N.V.
Joel S. Marcus and Barbara Allenstein Marcus 2
New England Biolabs 4
PhRMA Foundation 5
Promega Corporation 3
SAIC-Frederick, Inc.
SAP America, Inc.
University of Pittsburgh
$25,000 – $49,999
23andMe, Inc.
Actelion Pharmaceuticals Ltd. 2
Alexandria Real Estate Equities, Inc. 2
Amorfix Life Sciences Ltd.
BioClinica, Inc. 3
Biotechnology Industry Organization 5
The Breast Cancer Research Foundation
Burlington Coat Factory
Carestream Health, Inc.
Cubist Pharmaceuticals, Inc. 2
Dell Inc. *
James H. and Christina W. Donovan
Estée Lauder Companies Inc. 2
Forest Laboratories, Inc. 2
Friends of Cancer Research 3
Estate of Jack Gramlich 2
Hogan Lovells * 3
Medpace, Inc. 4
Meso Scale Diagnostics, LLC. 4
Dr. and Mrs. Paul M. Montrone 15
Drs. Martin J. and Ann Murphy 7 In honor of Charles A. Sanders
Nabriva Therapeutics AG 2
Oregon Health & Science University
Qualcomm, Incorporated 4
RottaPharm I Madaus 2
Mr. Gerald R. and Dr. Ellen V. Sigal 10
SoBran, Inc. 2
Susan G. Komen for the Cure
Synarc, Inc. 5
Trius Therapeutics, Inc. 2
The Foundation for the NIH would like to thank the many
corporations, private foundations, associations and
individuals who generously provided financial and in-kind
support to the Foundation and its programs during 2012.
Restricted gifts support many varied initiatives, including
complex biomedical research programs; educational
efforts such as fellowships, lectures and symposia that
train scientists and help them build their careers; and
specific laboratories or areas of scientific research at the
NIH. Unrestricted gifts support core operations and enable
the Foundation to develop emerging program areas and
new partnerships.
The Foundation is very efficient in managing the private
sector’s investment. Of every dollar spent by the
Foundation, 94 cents are used to support programs and
just 6 cents for administration and fundraising. In testament
to the FNIH’s efficient management of your investment,
we have been awarded—for six consecutive years—four
stars by Charity Navigator. This top ranking recognizes that
we execute our mission in a “fiscally responsible way, and
outperform most other charities.” The Foundation gratefully
acknowledges the following donors and partners who
made gifts or pledges of $250 or more during 2012.
The Foundation for the NIH makes every attempt to list
donors according to their wishes. Please call 301.402.5311
if you have any questions.
Foundation for the National Institutes of Health WWW.FNIH.ORG | 23
United HealthCare Services, Inc. 2
George and Trish Vradenburg Co-Founders USAgainst Alzheimer’s
$10,000 – $24,999
Anonymous
Bernard W. Abrams Family Foundation, Inc. 3 In memory of Bernard W. Abrams
Affymetrix
Alliance for Aging Research
American Association for Clinical Chemistry and the Wallace H. Coulter Foundation
AMS Foundation for the Arts, Sciences and Humanities
Elizabeth Arden Spas, Inc.
Autism Speaks, Inc.
Basilea Pharmaceutica International Ltd. 2
Buffy and William Cafritz 9 In honor of Charles A. Sanders
CHDI Foundation
Chiesi Farmaceutici S.p.A. 3
Corgenix Medical Corporation *
Crescendo Bioscience
Stephen P. A. Fodor, Ph.D.
Forest City Enterprises, Inc.
Miles Gilburne and Nina Zolt 3
Grifols
International Biomedical Research Alliance 2
Kite Pharma, Inc.
Legacy Venture V, LLC
Howard H. and Jacqueline K. Levine 2
Freda C. Lewis-Hall, M.D., FAPA 2
Steven C. Mayer
McCann Worldwide
Merck Sharp & Dohme Corp. * 15
National Pharmaceutical Council 2
Erik F. Neva
Kristin Neva
Bob and Sally Newcomb 2
Estate of Jennifer R. Price
Jillian Sackler, D.B.E. 10
Jane M. Sayer, Ph.D. 11
SOHO Publishing Company
Talecris Biotherapeutics, Inc
Joseph M. and Madeline Wikler In honor of John Gallin
$5,000 – $9,999
Anonymous
The Agouron Institute
Arie Belldegrun
Ronald and Barbara Berke 3 In memory of Jennifer Berke
Luther W. Brady, M.D. 6
Esther and James H. Cavanaugh 5
Cempra Pharmaceuticals 2
Ms. Laura Curtin 4 In memory of Richard Curtin
James V. Kimsey
John L. Latka, Jr. In memory of Lillian O. Latka
Life Technologies *
Jean Linton 10
Meridian Hospitals Corporation
Drs. Roslyn and Jerome Meyer
Mohr Davidow Ventures
Morrison & Foerster LLP
Nanticoke Memorial Hospital
Steven and Jann Paul 2
Quidel Corporation *
Radiological Society of North America 4
Skacel Collection
Solomon H. and Elaine B. Snyder 12
Nina Solarz 3 In memory of Stephen Solarz
SunTrust Banks, Inc. 2
United States Pharmacopeial Convention 2
University of British Columbia 2
Steve and Chris Wilsey 5
Stewart K. Wilson In memory of Blaise Ribet
$2,500 - $4,999
Anonymous
American Society For Pharmacology and Equipment Therapuetics
BIO Ventures for Global Health
BioVendor Inc. *
Joseph M. Feczko, M.D. and Leighton K. Gleicher 5
Foundation for Advanced Education in the Sciences
GlaxoSmithKline * 14
Fred and Noreen Hassan 3
Dr. and Mrs. Garry A. Neil
Donna Nichols 3
In memory of Jay NicholsLenore R. Salzman 15
In memory of Dr. Norman P. Salzman
Dr. and Mrs. Charles A. Sanders 16
Simon Property Group 3
The Eddie and Jo Allison Smith Family Foundation 2 In honor of Lanier Swann and Chris Battle
Michael and Lynda S. Swann
In honor of Chris and Dena BattleSamuel O. Thier, M.D. and Paula Thier 7
Ullmann Family Foundation 4
$1,000 – $2,499
Anonymous
Ronald A. and June L. Ahrens
Shana Alexander Charitable Foundation Dr. and Mrs. William G. Barsan 3
Becton Dickinson and Company
The Honorable and Mrs. William McCormick Blair, Jr. 14
Mr. Zachary T. and Dr. Kathy Bloomgarden 4
Boehringer Ingelheim Pharmaceuticals, Inc. * 5
Samuel and Gail Broder 12
Mr. Charles Cerf and Dr. Cynthia E. Dunbar 3
Mark Chee, Ph.D.
Carole Corcoran In memory of Stephen Solarz
Stewart Daniels 4 In memory of Anita Dickler
Robert and Betsey Drucker 2
Amelia Eisch and Shae Padrick In memory of Dr. Rolf H. Joho
The Essence of Red Committee 2
Ronald G. Evens, M.D. 6 In honor of John Gallin
James M. Felser, M.D. 3
Drs. Ernesto I. and Maria C. Freire
Paul J. Gattini
Stanley and Eve Geller 2 In memory of Norman Salzman
Howard Gershenfeld, M.D., Ph.D. In memory of Rolf Joho
Eli Glatstein, M.D. 9
GlycoMimetics, Inc.
GlycoSyn (IRL)
Gary and Lynn Grossman 2
Kay A. Hart 2
Harley Anderson Haynes, M.D. 3
Eric Hirschhorn 2 In memory of Stephen Solarz
Eva C. Holtz 3
IQ Solutions 3
Jen Family Charitable Trust
Jimmy Beans Wool
Daniel L. Kastner, M.D., Ph.D.
Bernard H. and Georgina E. Kaufman 3
The Latin Family In honor of Todd Latin
Jonathan D. Levine 2
Omega C. Logan Silva, M.D., MACP
James and Marie Malaro 2
The Honorable and Mrs. Frederic V. Malek
Miltenyi Biotec, Inc.
Fred and Jakki Nance
Brian R. O’Neill 10
Matthew W. O’Neill 6
Robyn Painter In memory of Jay Nichols
Ron and Joy S. Paul and Family 3 In honor of Fred Sommer’s Birthday
Jared Pellegrini and and Team HOPESTRONG In memory of Matt Koehler
Amy and John Porter 13
Eric K. Ralph
Robert E. Roberts, Ph.D. 4
Estate of Frances H. Saupe 6
Alex and Renee Shumate
Sigma-Aldrich Corporation 4
Sandy and Heidi Sinick
Society for Glycobiology
Fred S. and Nancy T. Sommer 2
Mark A. Spiteri 7
Dr. and Mrs. James R. Stabenau
Joseph and Carole H. Stavenhagen
Stitch Red
The Drs. Tremoulet 4
Trendsetter Yarns
TRQSS Associates In memory of Wesley LaPorte
George F. Vande Woude, Ph.D. 2
Jon and Kristin Vaver 5
Robert J. and Jean S. Warrick
Waters Corporation
Howard M. and Nancye C. Weisberg 4
Robert A. and Peggy A. Welch
$500 – $999
Anonymous
Ann Ashby and Ron Kopicki 2
Association of American Medical Colleges
Berroco, Inc. 2
Tino and Dawn Calabia 2
Dan Balliet and Jan Carlson 4
J.R. Clark and Family
Craig Corbitt and Nancy Stoltz 3
Drs. Paul J. and Faith B. Davis
Janet S. DeGilio 3
Denise Interchangeable Knitting Needles 2
Dreamcatcher Productions, Inc.
Carol and John Eddy 5 In honor of Garth Eddy
Margaret Emery In memory of Wesley LaPorte
Nicholas M. and Jacqueline E. Ferriter 3
Festival Sports, Inc.
James and Karen Gavic 3
Peggy J. Gerlacher 15 In memory of John D. Gerlacher
Ken and Yvette Guidry 6
Mary Frances Cotch and B. Fenton Hall 8
Jennifer D. Hendricks
Jerry Hornstein
Susan Horowitz
Laurel Jacobson 3 In memory of Stephen Jacobson
Michael M. Kaback, M.D.
Charles E. Kaufman Medical Fund
Ronald and Susan Krall
Jeremy Krasner
Erica Joyce Lam
Dr. and Mrs. Ronald W. Lamont-Havers 3
Lantern Moon, Inc.
Ron Levenbaum, D.M.D.
Russell C. Libby, M.D. and Mary Schmidt Libby, M.D.
Jim and Wendy Maiwurm
Mattlin Foundation 4
Anthony B. Mauger
Daniel Mayer
Luke McCrone
Daniel Merced 2
Dr. Gilbert S. Omenn and Mrs. Martha Darling 2
Susanne N. O’Neill
Frank M. and Lillian W. Orson
Premier Yarns Inc.
Armand and Lissette Rodriguez 2
Robert and Marjorie Rosenberg
Alissa Roston
Dr. and Mrs. Howard K. Schachman 8
Tiffany Smith
Dr. and Mrs. Sheldon Spector
Tom and Meg Stanton
Jonathan Taylor In memory of Dennis Taylor
Nitish Thakor
Travelers Companies, Inc.
Joseph Walker and Mary Oates Walker
John P. Walsh and Annette Deshotels
Michael and Marianne Walter 2 In honor of Matt Walter
Gail G. Weinmann
Mrs. Henry P. Wheeler 12
John H. Wilson 4
Brian and Brittany Woolfolk
Laura Zander
$250 – $499
Anonymous
Drs. Bryan and Donna Arling 8
Artyarns
Jill H. Barr 4
In memory of John BarrAnn M. Beck 5
Joan Beck 2
Blue Sky Alpacas
Don and Anne Bordine
In memory of Jan WeymouthAmy Brown
John and Kendra Burlingame
Cambridge Isotope Laboratories, Inc. 3
Larry and Anne Carrick In memory of Wes LaPorte
Daniel Carucci, M.D., M.Sc., Ph.D. 3
Patrick Chin In memory of Enid Chin
Churchmouse Yarns & Teas
Raymond W. Clement 4
Peter Collins, Ph.D. 4
ComputerShare
Peter H. Crawford
Susan G. Davis 4
James P. and Jacqueline M. Dougherty
Margaret Barr Eastman In memory of John Barr
Scott and Anedi Edelstein
Elsevier, Inc. 5
John Ferrara In honor of Nick Silano
Jason and Gloria Garver 6
Caite, Brian, and Benjamin Gilmore 2
Drs. David Golan and Laura Green 2
William D. Goldring In memory of Wesley LaPorte
Joseph Grossman
Katherine J. Guire 2
Joe W. Harris 2
Carolyn H. Hayman In honor of Howard Fine
C.T. and Moira H. Hill In memory of Terry Phillips
Arthur E. Holtz
E.A. Holtzman Foundation 2 In honor of Nina Solarz’s Birthday
Alphonse and Carol Ilekis
Interweave Store
Pamela Jeffcoat 4 In memory of Emma Timcho
Richard Jonas and Katherine Vernot-Jonas 5
Koigu Wool Designs
Johanna L. Kool
In honor of James BalowJody A. Kris
Klaus P. and Lisa M. Kutschke
Ned and Beth Levine
Laurie Levy In honor of Michael Robinson and Hilary Cramer
Dr. Adel A. Mahmoud and Dr. Sally Hodder 3
Herb and Marcia Marks
Dr. Anne Alexander Marshall and Mr. Davis Marshall 8
Roger A. and Barbara Michaels 3
Wilson T. and Christy R. Mistr 2 In honor of Chris Battle
Bayard H. Morrison, III, M.D.
Adam Mullins In memory of Wesley J. Laporte
Jim and Marcia Murphy
Jack Nadler
Namaste Inc.
Reverend and Mrs. Robert H. Naylor 3
Christopher J. Ohlandt
Stephen J. Paulino
Plymouth Yarn Company
Mara Polan 2 In honor of Fred Sommer
William J. Price 3
Dr. Paul Ra In memory of Wesley LaPorte
Christina Reyna 2
James and Lora Rodenberg 3
Tali Rombro In memory of Jane Lochary
Michelle Schumaker 2
Marilyn M. Seastrom
Norma Sessions
Stephen C. Shyne
Walt and Rachel Sirene
The Spence Family
T & C Imports
William Tolentino and Andre Bailey 4
James B. Tucker 5
Julie A. Tune 2
Beth Turetsky
In honor of Nina Solarz’s BirthdayPaula Warrick
Robert C. Watson and Debra D. Petersen3
David Wholley and Mary M. O’Crowley
Ingrid Wiley 4
Howard and Julie Wolf-Rodda 6
Joyce A. Yarington 9
In honor of Chris Harp
Joel Yesley 5
Charles W. Zimmerman 5
Matthew Zimmerman 3
* indicates Gifts in Kind
[superscript] indicates number of years of consecutive giving
Donors (continued)
Foundation for the National Institutes of Health WWW.FNIH.ORG | 25
HONORARIUM GIFTS
You can honor a friend or family member for an important occasion with a gift to
the Foundation for the NIH. It is a wonderful way to send good wishes for a birthday
or anniversary, thanks to a friend or doctor, or congratulations for retirement, a job
well done or graduation. Please include the name and address of the individual
being honored so that acknowledgement of your donation can be sent. In 2012, the
Foundation received gifts in honor of the following individuals.
LEGACY SOCIETY
The Legacy Society recognizes individuals who have informed us that they have
named the Foundation for the NIH as a beneficiary in their will or estate plan. These
legacy gifts can support a specific NIH program, area of research or other identified
need, or they may provide unrestricted support to the Foundation. We thank the
following individuals who have named the Foundation as a beneficiary.
Anonymous
Judy Belous
The Honorable and Mrs. William McCormick Blair, Jr.
Paula L. and William C. Bradley
Buffy and William Cafritz
Patricia S. and Ken Kohlen
Drs. Zell and Emily Kravinsky
Patricia Nowosacki
Estate of Jennifer Price
Robert E. Roberts, Ph.D.
Estate of Frances H. Saupe
Jane M. Sayer, Ph.D.
Dr. and Mrs. Robert F. Wagner
Susan M. Wall, M.D.
MEMORIAL GIFTS
Contributions are given to the Foundation for the NIH at the request of family members
in memory of loved ones. These generous contributions enhance our ability to support
the NIH in its mission to improve health, by forming and facilitating public-private
partnerships for biomedical research, education and training. We extend our sympathies
to the family and friends of those memorialized below.
Bernard W. Abrams
Janet Albright
John H. Allred
Leona Anderson
Julius Axelrod
Stuart Baker
John L. Barr
Karol Bell
Jenny Berke
Deborah R. Boshers
Thurston H. Boyd
Al Butler
Bennett Camhi
Veronica S. Cassell
Enid Chin
Sharon Christenson
Richard Curtin
Frank Delk
Anita Dickler
Tom Doering, Sr.
Maureen Dough
Saundra P. Duboff
Marilyn Feit
Henry Gelfand
John D. Gerlacher
Martin Greenberg
Natalie Greenberg
Alton D. Gutshall
Chris Harp
Donald Helfman
Willard W. Henley
Agneta Hughes
Nicholas P. Humy
Stephen W. Jacobson
Rolf H. Joho
Walter Jud
Roberta Kama
Libby Kamaroff
Meagan Kelly
Thomas J. Kennedy
Matt Koehler
Wesley J. LaPorte
Lillian O. Latka
Karen S. Leo
Stephen Liptak
Jane Lochary
Richard H. Madden
Wanda S. Merriweather
John N. Miller
Stan C. Nebinski
Jay Nichols
Casimir J. Noga, Sr.
Jean S. Noga
Dean R. O’Neill
Terry L. “Chipper” Phillips
John Ramos
Blaise Ribet
Zvenia Romaniw
Kathleen Rudis
Norman P. Salzman
Elmer D. Sattler
Arthur G. Schatzkin
Florence Schoener
Lowell and Yin Schurman
Thomas Sims
Reba Sloane
Stephen Solarz
Nathan W. Synan
Dennis Taylor
Emma Timcho
MOM Wagner
Allison Walden
Janice Weymouth
Thet Win Lwin
Sheldon Wolpin
Deborah Wright
William J. Yates
James E. Balow
Chris Battle
Gennady Bratslavsky
Masako Chen
Emily Chew
Hilary Cramer
Garth M. Eddy
Howard A. Fine
John I. Gallin
Eric Green
Barry Grossman
Rozelle Grossman
Stephanie L. James
Mayer Katz
Nancy Katz
Nicholas Kirincich
Todd Latin
Philip Leder
Russell R. Lonser
Claire Lowther
Miguel Materin
Janet Orloff
Jean Pouyes
Lisa Reinish
Shelly Reinsch
Michael Robinson
Lissette Rodriguez
Saul Roseman
Ann Sanders
Charles A. Sanders
Nick Silano
Rene K. Smith
Nina Solarz
Fred S. Sommer
Lanier Swann
Betsy Templeton
Matt Walter
Stuart H. Yuspa
FINANCIALS
“The Foundation for the National Institutes
of Health is successful because of the depth
of the partnerships we engender — from a
sports organization, knitters, pharmaceutical
companies, foundations, individuals and others.
This diversity allows us to continue to bring
wide-ranging talents to bear on the most
critical health care needs.”
Paul Montrone, Ph.D., Chairman, Perspecta Trust; Executive Chairman and Founding Partner, Liberty Lane Partners; FNIH Board Member
Foundation for the National Institutes of Health WWW.FNIH.ORG | 27
Financial SummaryREVENUE AND SUPPORT 2012 2011
Contributions 57,116,585 53,307,415
Grants 1,338,963 7,184,662
Administrative fee 260,551 336,864
Government appropriations 514,000 486,000
Investment earnings 247,254 83,763
In-kind contributions 250,927 2,037,266
Donated services 41,000 44,892
Other revenue 343,501 -
Reduction of future pledges (1,275,000) -
TOTAL REVENUE AND SUPPORT 58,837,781 63,480,862
EXPENSES AND CHANGES IN NET ASSETS
PROGRAM SERVICESFellowships and training programs 1,325,295 1,486,681
Memorials, awards and events 1,246,180 3,712,399
Capital projects 35,100 38,516
Research partnerships 45,183,190 44,259,013
TOTAL PROGRAM SERVICES 47,789,765 49,496,609
SUPPORTING SERVICES Management and general 3,105,327 2,944,238
Fundraising 145,093 145,190
TOTAL SUPPORTING SERVICES 3,250,420 3,089,428
TOTAL EXPENSES 51,040,185 52,586,037
CHANGE IN NET ASSETS 7,797,596 10,894,825
NET ASSETS BEGINNING OF YEAR 84,432,944 73,538,119
NET ASSETS AT END OF YEAR 92,230,540 84,432,944
2012 REVENUES 2012 EXPENSES
The Foundation’s audited statements are available on request.
Grants 2%Other Revenue 3%
Contributions 95% Research Partnerships 89%
Education and Events 5%
Management and Fundraising 6%
2012 Foundation for the NIH Staff President’s Office Maria C. Freire, Ph.D.President and Executive Director
Ann Ashby, M.B.A.Deputy Executive Director
Michele Jezycki, M.A.O.M.Director, Human Relations(Contractor)
Felicia GrayExecutive Assistant
Elizabeth S. JohnsExecutive AssistantOperations
Kathy GuireOperations Officer
Finance Julie Tune, C.P.A., C.F.E.Chief Financial Officer
Eva CoyneAccounting Manager
Cathy MartinSenior Accountant
Noemi B. RodriguezStaff Accountant
Peggy J. GerlacherOperations Associate
Events and Marketing
Laura PayneDirector
Kai YeeWeb Administrator
Kimberly O’SullivanCommunications Officer
Jolie MakEvents Coordinator
Jasmin MilesEvents Coordinator
Andrea HickmanEvents Coordinator
Development
Julie Wolf-Rodda, M.A.Director, Partnership Development
Andrea Baruchin, Ph. D.Director, NIH Relations
Erika TarverNIH Projects Officer
Rob DruckerPartnership Development Officer
Caite GilmorePartnership Development Officer
Jennifer IlekisPartnership Development Officer
Paris L.A. MoorePartnership Development Officer
Will TolentinoDevelopment Systems Administrator
Annie BradfieldExecutive Assistant
Science Administration
Stephanie James, Ph.D.Director of Science and Director, Grand Challenges in Global Health
Michael Gottlieb, Ph.D.Deputy Director of Science
Dennis Lang, Ph.D.Senior Program Coordinator, MAL-ED(Contractor)
Karen Tountas, Ph.D.Scientific Program Manager, MAL-ED
Susan Powell, M.T.S.Senior Grants Manager
Magda GalindoAssistant Grants Manager
Susan Wiener, M.A.Project Manager, Grand Challenges in Global Health
Gail Levine, M.A., C.R.C.C.Scientific Program Manager, CTC-VIMC
Anna Sambor, M.S.Program Manager
Tiffany FrancisExecutive Assistant
OMOP
Tom Scarnecchia, M.S.Executive Director(Contractor)
Emily Welebob, R.N., M.S.Senior Program Manager(Contractor)
Mark KhayterOMOP Lab Team – Lead Engineer
Biomarkers Consortium
David Wholley, M.A.Director
Maria Vassileva, Ph.D.Scientific Program Manager, Metabolic Disorders
Sonia Pearson-White, Ph.D.Scientific Program Manager, Cancer
Judy Siuciak, Ph.D.Scientific Program Manager, Neuroscience
Steven C. HoffmanScientific Program Manager, Inflammation and Immunity
Jessica RatayClinical Project Manager Cheryl MelencioExecutive Assistant
Foundation for the National Institutes of Health WWW.FNIH.ORG | 29
DESI
GN: D
on S
chaa
f & F
riend
s, In
c. |
ww
w.d
sfrie
nds.
com
2012 Board of DirectorsCharles A. Sanders, M. D. (Chairman)Retired Chairman and CEO, Glaxo, Inc.
Mrs. William McCormick Blair, Jr. (Secretary)Director Emeritus, Albert and Mary Lasker Foundation
Kathy Bloomgarden, Ph.D.Chief Executive Officer, Ruder Finn, Inc.
Mrs. William (Buffy) N. CafritzTrustee, The John F. Kennedy Center for the Performing Arts
Mr. James H. DonovanPartner, Goldman Sachs & CompanyAdjunct Professor, University of VirginiaTrustee, Dana-Farber Cancer Institute
Joseph Feczko, M.D.Retired Senior Vice President and Chief Medical Officer, Pfizer Inc
Maria C. Freire, Ph.D.President and Executive Director, Foundation for the NIH
Mr. Miles GilburneManaging Member, ZG Ventures, LLC
Paul L. Herrling, Ph.D.Chairman, Novartis Institute for Tropical Disease
Ronald L. Krall, M.D.Former Senior Vice President and Chief Medical Officer, GlaxoSmithKline
Sherry LansingChief Executive Officer, The Sherry Lansing Foundation
Freda C. Lewis-Hall, M.D.Chief Medical Officer, Senior Vice President—Chief Medical Office, Pfizer Inc
Edison T. Liu, M.D., Ph.D.President and Chief Executive Officer, The Jackson Laboratory
Ms. Ann LurieLurie Investments, Inc.
Mr. Joel S. MarcusChairman/CEO/President/Founder, Alexandria Real Estate Equities, Inc.
Mr. Steven C. MayerRetired Executive Vice President and Chief Financial Officer, Human Genome SciencesRetired Founder and Chief Executive Officer, CoGenesys, Inc.
Paul M. Montrone, Ph.D. (Treasurer)Chairman, Perspecta Trust
Martin J. Murphy, Jr., Ph.D.Chairman and Chief Executive Officer, AlphaMed Consulting, Inc.
Garry A. Neil, M.D.Partner, Apple Tree PartnersHead, R&D Apple Tree Pharmaceuticals
Steven M. Paul, M.D.Director, Helen and Robert Appel Alzheimer’s Disease Research InstituteProfessor of Neuroscience, Psychiatry, and Neurology, Weill Cornell Medical College
The Honorable John Edward Porter (Vice Chairman for Policy)Hogan Lovells US, LLP
Mrs. Jillian Sackler, D.B.E.President and Chief Executive Officer, AMS Foundation for the Arts, Sciences and Humanities
Lily SafraChairwoman, The Edmond J. Safra Philanthropic Foundation
Ellen V. Sigal, Ph.D.Chairperson and Founder, Friends of Cancer Research
Solomon H. Snyder, M. D. (Vice Chairman for Science)Distinguished Service Professor of Neuroscience, Pharmacology & Psychiatry, Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine
Ms. Nina K. SolarzFormer Executive Director, Peace Links and the Fund for Peace
Samuel O. Thier, M.D.Professor of Medicine and Health Care Policy, Emeritus, Harvard Medical School, Massachusetts General Hospital
Anne WojcickiCo-Founder, 23andMe
Honorary Directors
Luther W. Brady, M.D.Distinguished University Professor, Hylda Cohn / American Cancer SocietyProfessor of Clinical Oncology, and Professor, Department of Radiation Oncology, Drexel University College of Medicine
Patrick C. Walsh, M.D.University Distinguished Service Professor, James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions
Director Emeritus
Paul Berg, Ph.D.Cahill Professor in Biochemistry (Emeritus), Stanford University School of Medicine
Ex Officio Non-Voting Directors
Francis S. Collins, M.D., Ph.D.Director, National Institutes of Health
Margaret Hamburg, M.D.Commissioner, Food and Drug Administration
Partners for Innovation, Discovery, Health
9650 Rockville Pike Bethesda, MD 20814-3999 USA
301.402.5311
www.fnih.org
All rights reserved. This material may be quoted or reproduced without charge for noncommercial purposes only; however, please acknowledge the source.
The full text of this report is also available online at www.fnih.orgPrinted on Rolland Enviro100 Satin, which contains 100% post-consumer fiber, is EcoLogo and is Processed Chlorine Free certified.
100%